Moderna says its COVID-19 vaccine is 96% effective in kids ages 12-17

Moderna said May 6 its COVID-19 vaccine is 96 percent effective in adolescents ages 12-17, according to an initial analysis of a phase 2/3 trial.

The vaccine was well tolerated among the trial's 3,235 participants. The trial included 12 COVID-19 cases that started 14 days after the first dose.